Deschner Max, Vasanthamohan Lakshman, Zayed Sondos, Lazo-Langner Alejandro, Palma David, D'Souza David, Omar Gilani Syed, Gabriel Boldt R, Solh Ziad
Department of Medicine, Western University, London, ON, Canada.
Department of Oncology, Lakeridge Health, Oshawa, ON, Canada.
Clin Transl Radiat Oncol. 2021 Dec 16;33:23-29. doi: 10.1016/j.ctro.2021.12.002. eCollection 2022 Mar.
Packed red blood cell (RBC) transfusion is frequently used in patients undergoing radiotherapy (RT) because retrospective data suggest that anemic patients may respond sub-optimally to RT. No high-quality evidence currently exists to guide transfusion practices and establish hemoglobin (Hb) transfusion thresholds for this patient population, and practice varies significantly across centers. This systematic review investigated whether maintaining higher Hb via transfusion in radiation oncology patients leads to improved outcomes.
We performed a literature search of studies comparing RBC transfusion thresholds in radiation oncology patients. Included studies assessed patients receiving RT for malignancy of any diagnosis or stage. Excluded studies did not evaluate Hb or transfusion as an intervention or outcome. The primary outcome was overall survival. Secondary outcomes included locoregional control, number of transfusions and adverse events.
One study met inclusion criteria. The study pooled results from two randomized controlled trials that stratified anemic patients with head and neck squamous cell carcinoma to RBC transfusion versus no transfusion. The study found no significant differences in overall survival or locoregional control after five years, despite increased Hb levels in the transfused group. We conducted a narrative review by extracting data from 10 non-comparative studies involving transfusion in patients receiving RT. Results demonstrated no consistent conclusions regarding whether transfusions improve or worsen outcomes.
There is a lack of data on the effects of RBC transfusion on outcomes in patients undergoing RT. Well-designed prospective studies are needed in this area.
浓缩红细胞(RBC)输血常用于接受放疗(RT)的患者,因为回顾性数据表明贫血患者对放疗的反应可能不理想。目前尚无高质量证据来指导输血实践并确定该患者群体的血红蛋白(Hb)输血阈值,而且各中心的做法差异很大。本系统评价调查了在放射肿瘤学患者中通过输血维持较高的Hb水平是否能改善预后。
我们对比较放射肿瘤学患者RBC输血阈值的研究进行了文献检索。纳入的研究评估了因任何诊断或分期的恶性肿瘤而接受RT的患者。排除的研究未将Hb或输血作为干预措施或结局进行评估。主要结局是总生存期。次要结局包括局部区域控制、输血量和不良事件。
一项研究符合纳入标准。该研究汇总了两项随机对照试验的结果,这两项试验将头颈部鳞状细胞癌贫血患者分为RBC输血组和未输血组。该研究发现,尽管输血组的Hb水平有所升高,但五年后的总生存期或局部区域控制方面没有显著差异。我们通过从10项涉及接受RT患者输血的非对照研究中提取数据进行了叙述性综述。结果表明,关于输血是改善还是恶化结局,尚无一致结论。
缺乏关于RBC输血对接受RT患者结局影响的数据。该领域需要设计良好的前瞻性研究。